SEC Filing Summary

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc., reported a series of transactions on September 16, 2026. Bizily acquired 1635 shares of common stock at $4.14 per share and subsequently disposed of 1635 shares of common stock at $13.65 per share. These transactions were made pursuant to a 10b5-1 trading plan. Additionally, Bizily reported a disposition of a stock option (right to buy) with an exercise price of $4.14, underlying 1635 shares of common stock. The option award vests monthly over four years. Following these transactions, Bizily owns 10252 shares directly and has 58066 shares underlying vested options.